Literature DB >> 7110302

Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus.

J G Wilson, W W Wong, P H Schur, D T Fearon.   

Abstract

The erythrocytes of patients with systemic lupus erythematosus have been shown to have a decreased number of receptors for the major cleavage fragment of the third component of complement (C3b). We studied the basis for this decreased number of C3b receptors by measuring the uptake of anti-C3b-receptor antibody on cells from 113 normal subjects, 38 patients with systemic lupus erythematosus, 14 of their spouses, and 47 of their relatives. The normal subjects had 5014 +/- (mean +/- S.E.M.) receptor sites per cell, but the patients and their relatives had significantly fewer sites--2809 +/- 241 and 3167 +/- 196, respectively (P less than 0.0005). The number of sites in the patients' spouses did not differ from normal (P greater than 0.3). Three phenotypes, indicated by the numbers of receptors, occurred in the normal population; a high phenotype (HH, with 5500 to 8500 sites per cell), an intermediate phenotype (HL, with 3000 to 5499), and a low phenotype (LL, less than 3000). These three phenotypes were present in 34, 54, and 12 percent, respectively, of the normal subjects; in contrast, 5, 42, and 53 per cent of patients had these respective phenotypes. Pedigree analyses indicated that these phenotypes were inherited in an autosomal codominant manner. We conclude that the decreased number of C3b receptors in lupus is inherited, not acquired.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7110302     DOI: 10.1056/NEJM198210143071604

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  89 in total

1.  Expression and localization of proteins of the complement system in human skin.

Authors:  N Dovezenski; R Billetta; I Gigli
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

2.  Dual role of erythrocyte complement receptor type 1 in immune complex-mediated macrophage stimulation: implications for the pathogenesis of Plasmodium falciparum malaria.

Authors:  M Odera; W Otieno; C Adhiambo; J A Stoute
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

3.  Relationships between antibodies against human soluble complement receptor 1 (hsCR1) from various species.

Authors:  E V Ruggieri; P J Bugelski; J M Kaplan; D Everitt; J Lipani; D K Jorkasky; S C Boike; F DeClement; F D Moore; D J Herzyk
Journal:  J Clin Immunol       Date:  1996-03       Impact factor: 8.317

4.  In vivo binding of circulating immune complexes by C3b receptors (CR1) of transfused erythrocytes.

Authors:  Y Inada; M Kamiyama; T Kanemitsu; H Ikegami; K Watanabe; W S Clark; Y Asai
Journal:  Ann Rheum Dis       Date:  1989-04       Impact factor: 19.103

5.  Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare.

Authors:  D J Birmingham; K F Gavit; S M McCarty; C Y Yu; B H Rovin; H N Nagaraja; L A Hebert
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

6.  Regulation of circulating immune complexes by complement receptor type 1 on erythrocytes in chronic viral liver diseases.

Authors:  J Miyaike; Y Iwasaki; A Takahashi; H Shimomura; H Taniguchi; N Koide; K Matsuura; T Ogura; K Tobe; T Tsuji
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

7.  Polymorphism of human erythrocyte C3b/C4b receptor.

Authors:  T R Dykman; J L Cole; K Iida; J P Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

8.  Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.

Authors:  A Nicholson-Weller; J P March; S I Rosenfeld; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

9.  Autoantibody to the C3b/C4b receptor and absence of this receptor from erythrocytes of a patient with systemic lupus erythematosus.

Authors:  J G Wilson; R M Jack; W W Wong; P H Schur; D T Fearon
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

10.  Erythrocyte complement receptor type 1 in non-SLE rheumatic diseases.

Authors:  J H Yen; H W Liu; S F Lin; T P Chen
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.